EGFR and triple-negative breast carcinoma: For example, scRNA-seq was used to assess the triple-negative breast cancer patient derived cells that respond to epidermal growth factor receptor (EGFR) therapy and found an increased presence of enhanced stem-cell-like/mesenchymal characteristics in these cells [199].